Clinical trials: Vitreomacular Adhesion
- Condition Vitreomacular Adhesion
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Vitreomacular Traction, Vitreomacular Adhesion
Assessment of Patients Treated With JETREA® for Vitreomacular Traction
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA®) over a 6-month follow-up period.
- Trial name
- NCT02035748
- Testing
- Ocriplasmin
- Volunteers
- 628 people
- Sponsor
- Alcon Research
Exudative Age-Related Macular Degeneration, Focal Vitreomacular Adhesion
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion.
- Trial name
- MIVI-5 (NCT00913744)
- Testing
- Ocriplasmin
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 100 people
- Sponsor
- ThromboGenics
Symptomatic Focal Vitreomacular Adhesion
A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion
Evaluate the safety and efficacy of ophthalmic intravitreal injection of ALG-1001 in human subjects with symptomatic focal vitreomacular adhesion
- Trial name
- NCT02153476
- Testing
- 2.0mg of ALG-1001, Balanced Salt Solution
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Allegro Ophthalmics, LLC
Symptomatic Vitreomacular Adhesion
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.
- Trial name
- NCT01889251
- Testing
- Ocriplasmin
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Alcon Research
Vitreomacular Traction, Vitreomacular Adhesion
Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.
- Trial name
- NCT02322229
- Testing
- Ocriplasmin 0.125 mg in a 0.1 mL volume
- Where
- Australia
- Volunteers
- 62 people
- Sponsor
- Alcon Research
Vitreomacular Adhesion
Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
The objective of this trial is to evaluate the safety and efficacy of intravitreal microplasmin 125µg dose in subjects wiht focal vitreomacular adhesion.
- Trial name
- NCT00781859
- Testing
- 125 µg Ocriplasmin
- Where
- 41 sites in United States
- Volunteers
- 326 people
- Sponsor
- ThromboGenics
Vitreomacular Adhesion
Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
This trial will evaluate the safety and efficacy of microplasmin, administered as an intravitreal injection, in subjects with focal vitreomacular adhesion.
- Trial name
- NCT00798317
- Testing
- Ocriplasmin 125µg
- Where
- 48 sites in United States, Belgium and 5 more
- Volunteers
- 326 people
- Sponsor
- ThromboGenics
Vitreomacular Adhesion Including Macular Hole
Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.
- Trial name
- OASIS (NCT01429441)
- Testing
- Ocriplasmin
- Where
- 25 sites in United States
- Volunteers
- 220 people
- Sponsor
- ThromboGenics